Clinical Trial Update: Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating TQB2450 in combination with anlotinib for advanced acral malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acral Malignant Melanoma

Drugs mentioned

• Anlotinib (anlotinib)
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Acral Malignant Melanoma | Phase 1, Phase 2 | Status: UNKNOWN